RANGANATH RAO JAGANNATH MADANAHALLI,ARUMUGAM NAGARAJAN,ANSARI MOHD MUDABBIR,GUDLA CHANDRASEKHAR,PACHIYAPPAN SHANMUGAM,RAMALINGAM MANIVANNAN,GEORGE JENSON,ARUL GEORGE FERNANDA,BOMMEGOWDA Y KENCHEGOWDA
申请号：
NZ60682711
公开号：
NZ606827A
申请日:
2011.07.20
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed herein are compounds of general formula I, wherein the substituents are as defined in the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as agonists of GPR40 and as such are useful in the treatment of cognitive disorders, osteoporosis, inflammatory disorders, diabetes, obesity, hyperglycemia. glucose intolerance. insulin resistance, hyperinsulemia, hypercholesteremia, hypertension, hyper!ipoproteinemia, hyperlipidemia. hypertriglyceridemia, dyslipedemia, metabolic syndrome, syndrome X, cardiovascular disease. atherosclerosis, kidney disease, ketoacidosis, thrombotic disorders, nephropathy, diabetic neuropathy, diabetic retinopathy, sexual dysfunction, dermatopathy, dyspepsia, hypoglycemia. cancer and edema. Examples of particularly preferred compounds include: 3-{ 2-Fluoro-4-[(4-{ [(2Z)-2-(methoxyimino)-2-phenylethyl]oxy} benzyl)oxy]phenyl} propanoic acid 3-{ 4-[(4-{ [(2Z)-2-(4-Cyanophenyl)-2-(methoxyimino)ethyl]oxy} benzyl)oxy]-2-fluorophenyl} propanoic acid 2-{ 4-[{ 4-{ [(2Z)-2-(4-Cyanophenyl)-2-(methoxyimino)ethyl]oxy} benzyl)oxy]phenyl} cyclopropanecarboxylic acid Sodium 3-cyano-3-{ 4-[(4-{ [(2Z)-2-(4-fluorophenyl)-2-(methoxyimino)ethyl]oxy} benzyl)oxy] phenyl} propanoate.
